Effect of darbepoetin alfa on exercise tolerance in anemic patients with symptomatic chronic heart failure: a randomized, double-blind, placebo-controlled trial.
about
Erythropoiesis-stimulating agents for anaemia in chronic heart failure patientsCanadian Cardiovascular Society Consensus Conference guidelines on heart failure, update 2009: diagnosis and management of right-sided heart failure, myocarditis, device therapy and recent important clinical trialsPharmacotherapy for comorbidities in chronic heart failure: a focus on hematinic deficiencies, diabetes mellitus and hyperkalemia.The effect of erythropoietin on exercise capacity, left ventricular remodeling, pressure-volume relationships, and quality of life in older patients with anemia and heart failure with preserved ejection fraction.Prevalence, incidence, and prognostic value of anaemia in patients after an acute myocardial infarction: data from the OPTIMAAL trial.Effect of anemia correction on left ventricular structure and filling pressure in anemic patients without overt heart diseaseA secondary analysis of the CHOIR trial shows that comorbid conditions differentially affect outcomes during anemia treatment.The role of erythropoietin stimulating agents in anemic patients with heart failure: solved and unresolved questionsAnaemia and long term mortality in heart failure patients: a retrospective study.ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure 2008: the Task Force for the Diagnosis and Treatment of Acute and Chronic Heart Failure 2008 of the European Society of Cardiology. Developed in collaboration with theAnemia and heart failure: a cause of progression or only a consequence?Effects of blood transfusion on exercise capacity in thalassemia major patients.Anemia associated with chronic heart failure: current concepts.Baseline characteristics of patients in the Reduction of Events with Darbepoetin alfa in Heart Failure trial (RED-HF).Iron deficiency and heart failure: diagnostic dilemmas and therapeutic perspectives.Anemia and heart failure: a community study.Darbepoetin alfa exerts a cardioprotective effect in autoimmune cardiomyopathy via reduction of ER stress and activation of the PI3K/Akt and STAT3 pathways.Darbepoetin-alpha prevents progressive left ventricular dysfunction and remodeling in nonanemic dogs with heart failure.Recognition and treatment of anemia in the setting of heart failure due to systolic left ventricular dysfunction.Etiology and management of anemia in patients with heart failure: how much iron is missing?Cardiorenal anemia syndrome: do erythropoietin and iron therapy have a place in the treatment of heart failure?The role of correction of anaemia in patients with congestive heart failure: a short review.Differences in blood volume components between hyporesponders and responders to erythropoietin alfa: the heart failure with preserved ejection fraction (HFPEF) anemia trialPrevalence of anemia in heart failure and its effects on prognosis.Anemia in heart failure: pathophysiologic insights and treatment options.Cardiovascular effects of erythropoietin an update.Overview of emerging pharmacotherapy in chronic heart failure.Is there a role for erythropoietin in cardiovascular disease?ADQI 7: the clinical management of the Cardio-Renal syndromes: work group statements from the 7th ADQI consensus conference.Impact of erythropoiesis-stimulating agents on morbidity and mortality in patients with heart failure: an updated, post-TREAT meta-analysis.Erythropoietin and the heart: facts and perspectives.Erythropoiesis-stimulating agents and heart failure.Anemia in heart failure: an overview of current concepts.Anemia and iron deficiency in heart failure: mechanisms and therapeutic approaches.Anemia in chronic heart failure: can we treat? What to treat?Erythropoietin: a future therapy for failing hearts?Anemia and iron deficiency in heart failure.Distinguishing anemia and iron deficiency of heart failure: signal for severity of disease or unmet therapeutic need?Use of erythropoiesis-stimulating agents in the treatment of anemia in patients with systolic heart failure.Side effects of cytokines approved for therapy.
P2860
Q24241045-239C54FC-8915-48C2-AE7F-11CF3177582DQ24650348-D199F849-137A-4D0F-91EA-656E4310F46EQ30250020-F51FCCF3-7D21-4660-B299-515D41CF6F19Q30475623-5F866301-2BFD-4441-9CB4-14C2601D122EQ33433326-89948874-26DB-4791-973C-EDE2C30F4DADQ33912879-BD2FDC3F-9279-4CD2-BB0F-8DD32FCBEE1FQ33985849-FAD88DB5-5FBC-40E9-B79D-A3059736B6F2Q34065957-AB9AA6AF-1483-4817-B420-A400A9DF1917Q34406816-CDEBD8B4-C7B9-42C0-B63C-F7A271F2EC9BQ34830023-0BEEE45C-FD4A-4D59-A7E9-66C8C78D4075Q35252704-D6793452-F041-4027-8932-5F7304968016Q35641346-17E64B93-DE7B-4FE1-93E6-0D9E8ED9691CQ36600453-9CE1045D-CAB4-4955-9AE5-EC8AD76CA458Q36623051-936FBAD5-82F0-451D-A508-4DA13995E521Q36682182-738AB1CB-188F-4D64-B8DB-0772BEFA3C9EQ36882168-CBBF3BF4-6AEC-48E5-AA9F-7B32BF011BC4Q37008467-B39FCBF9-D467-4E1B-BD28-A2387032495DQ37038709-FA552B66-B164-4F24-83AC-B9CD30094275Q37076291-32FB2DA6-DECF-459B-B770-AF24A35867F6Q37078810-3975D625-2FDF-4E73-8292-0AB85BBAA837Q37138777-B5053D39-DFB4-4E43-8354-98BAE9727559Q37243581-866AFF5E-55EF-4F2A-845F-014749838641Q37330335-6F018C9C-C1C8-42E1-85AF-787EECC318B4Q37390743-93A7C420-1CE1-4018-8A5F-7ADF7A867444Q37445907-60BC66F4-D508-4485-A22A-B69E4C87684CQ37533151-6CF3D67A-CBA5-40E2-8AC4-FD56CC21784DQ37552943-70140E67-C1A4-4FCC-B450-085ADFCEE10AQ37661050-0760F313-F11D-476C-A35E-6549434AD426Q37759964-0D62D1F4-62FF-4FAF-8BD7-A29C37231C2AQ37762930-43F6AC05-61E2-4BD2-B38E-E3DA51BD3D98Q37798565-4D6EA938-D6B3-4923-BBA0-6BBD2A68CF02Q37802925-3D4631E0-4089-49C3-A2E0-3DC1C0A69BDEQ37822727-526B5883-EE1B-441D-989D-F046D0D4A72BQ37883005-7F61E172-9806-4671-A230-28F81347203EQ37943240-377736C8-ECBA-49E0-9CDF-6A14DD71EB56Q37952603-7D405FC0-A36F-48B6-B1E5-E1219FD548DDQ38039849-FEBAB029-7160-4FFB-9143-11C02C2C68C0Q38199991-08B95AC5-2BCF-41AC-A1C5-97857885F7FEQ38226494-5D3931E9-5C46-477C-B804-BC33B074FAF6Q38255698-10999CF5-48C0-49D1-B57C-DF4A6404EE77
P2860
Effect of darbepoetin alfa on exercise tolerance in anemic patients with symptomatic chronic heart failure: a randomized, double-blind, placebo-controlled trial.
description
2007 nî lūn-bûn
@nan
2007年の論文
@ja
2007年学术文章
@wuu
2007年学术文章
@zh
2007年学术文章
@zh-cn
2007年学术文章
@zh-hans
2007年学术文章
@zh-my
2007年学术文章
@zh-sg
2007年學術文章
@yue
2007年學術文章
@zh-hant
name
Effect of darbepoetin alfa on ...... ind, placebo-controlled trial.
@en
Effect of darbepoetin alfa on ...... ind, placebo-controlled trial.
@nl
type
label
Effect of darbepoetin alfa on ...... ind, placebo-controlled trial.
@en
Effect of darbepoetin alfa on ...... ind, placebo-controlled trial.
@nl
prefLabel
Effect of darbepoetin alfa on ...... ind, placebo-controlled trial.
@en
Effect of darbepoetin alfa on ...... ind, placebo-controlled trial.
@nl
P2093
P50
P921
P1476
Effect of darbepoetin alfa on ...... lind, placebo-controlled trial
@en
P2093
Andrew J S Coats
Darlington Okonko
Dylan Rosser
Joanna Szachniewicz
Ken McDonald
Nigel Baker
Philip A Poole-Wilson
Scott M Wasserman
Stefan D Anker
P304
P356
10.1016/J.JACC.2006.11.024
P407
P577
2007-02-05T00:00:00Z